ReviewMarine drugs2019
Sea Anemone Toxins: A Structural Overview.
Review in Marine drugs, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed.
- Stable yet shifting: Early toxin dynamics in typical and atypical clownfish-anemone symbioses.Toxicon: X · 2026Article
- Envenomations, stings, and traumas caused by marine invertebrates: from scientific facts to a forensic vision towards sustainable health and conservation strategies: a review.Archives of toxicology · 2026Review
- Investigating the Effects of Sea Anemone (Stichodactyla haddoni) Toxin on Potassium and Sodium Channel Gene Expression and Cell Death Mechanisms in A549 Cells.Marine biotechnology (New York, N.Y.) · 2026Article
- Ion Channel-Targeting Toxins: Structural Mechanisms of Activation, Inhibition, and Therapeutic Potential.Toxins · 2025Review
- Inhibitory Activity of Calcium and Sodium Ion Channels of NeurotoxicPharmaceuticals (Basel, Switzerland) · 2025Article
- Article
- Anthozoan Chemical Defenses: Integrating Compounds, Enzymatic Activities, and Omics-Based Discoveries.International journal of molecular sciences · 2025Review
- Article
- Article
- Transcriptomics-driven exploration of genetic variation and peptide discovery in the sea anemones Anthopleura midori and Actinia equina.Scientific reports · 2025Article
- A review on NLRP3 inflammasome modulation by animal venom proteins/peptides: mechanisms and therapeutic insights.Inflammopharmacology · 2025Review
- The proteotranscriptomic characterization of venom in the white seafanOpen biology · 2025Article
- Proteomic Analysis Is Needed to Understand the Vulnerability ofJournal of proteome research · 2025Article
- Molecular Insights into the Low Complexity Secreted Venom of Calliactis polypus.Genome biology and evolution · 2024Article
- Voltage-Gated KMarine drugs · 2024Review
- Diversity analysis of sea anemone peptide toxins in different tissues of Heteractis crispa based on transcriptomics.Scientific reports · 2024Article
- Synthesis and Hypoglycemic Effect of Insulin from the Venom of Sea AnemoneMarine drugs · 2024Article
- Article
- Isolation and cDNA cloning of four peptide toxins from the sea anemoneThe journal of venomous animals and toxins including tropical diseases · 2024Article
- Animal Venoms as Potential Source of Anticonvulsants.F1000Research · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Sea anemones produce venoms of exceptional molecular diversity, with at least 17 different molecular scaffolds reported to date. These venom components have traditionally been classified according to pharmacological activity and amino acid sequence. However, this classification system suffers from vulnerabilities due to functional convergence and functional promiscuity. Furthermore, for most known sea anemone toxins, the exact receptors they target are either unknown, or at best incomplete. In this review, we first provide an overview of the sea anemone venom system and then focus on the venom components. We have organised the venom components by distinguishing firstly between proteins and non-proteinaceous compounds, secondly between enzymes and other proteins without enzymatic activity, then according to the structural scaffold, and finally according to molecular target.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.